MICROCHIP TECHNOLOGY INCORPORATED (MCHP): what the price requires
At today's price, MICROCHIP TECHNOLOGY INCORPORATED (MCHP) is priced for today's economics sustained for ~16.7 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/MCHP
Headline
| Field | Value |
|---|---|
| Ticker | MCHP |
| Company | MICROCHIP TECHNOLOGY INCORPORATED |
| Current price | $84.77/sh |
| Composition | Mixed-signal Microcontrollers 50% / Analog 28% / Other 22% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 67.0% |
| Operating margin (mid-cycle) | 23.8% |
| Margin expansion implied | +43.2pp |
| Trailing margin (depressed year) | 6.9% |
| Must persist for | 16.7y |
| Multiple paid | 49x mid-cycle operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 12.4% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.5 years.
Reconcile: at the x-ray's 9.3% required return this reads ~9.7 years; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +0.06σ |
| sustained it ~10 years at this level | 15% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 14.84x | 2 | expensive |
| Earnings | 11.52x | 3 | expensive |
| Relative | 3.43x | 5 | expensive |
| Growth | 1.63x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.
Per-Model Detail (n=13)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $31.41 | 2.70x | yes | FCF base $0.9B, growth 9% (input: historical growth), terminal g 4.0%, WACC 8.3%, 6yr projection |
| DCF Exit Multiple | Growth | $72.53 | 1.17x | yes | Exit EV/EBITDA: 41.8x / 43.8x / 45.8x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $32.49 | 2.61x | yes | P/E 48.4x (blended: static sector reference 22x + trailing (TTM) 201x), scenarios: 40.2x / 48.4x / 56.6x (bear / base = reference held flat / bull), EV/EBITDA 24.34x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $4.56 | 18.59x | yes | BV/sh $11.79, ROE (TTM) 3.6%, ke 9.3% |
| Two-Stage Excess Return | Asset | $2.83 | 29.95x | yes | 5yr excess ROE then converge to ke=9.3% (excluded from median) |
| Discounted Future Market Cap | Growth | $52.04 | 1.63x | yes | Rev $4.7B, growth 9% (input: historical growth; tapered), Terminal P/S: 6.6x / 8.0x / 9.4x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $6.59 | 12.86x | yes | EPS $0.22, growth 30% (input: historical EPS growth), PEG=6.71 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $19.74 | 4.29x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $1.67B × (1−12%) / WACC 8.3% → EPV (no growth) |
| Residual Income | Asset | $2.13 | 39.80x | yes | BV $11.79 + 5yr PV of (ROE (TTM) 3.6% − Kₑ 9.3%) × BV; BV grows 2.3%/yr (excluded from median) |
| Graham Number | Asset | $7.64 | 11.10x | yes | √(22.5 × EPS $0.22 × BVPS $11.79) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $24.69 | 3.43x | yes | EBITDA $1.18B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $7.36 | 11.52x | yes | FCF $871.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $2.30 | 36.86x | yes | SBC-adj FCF $0.62B (FCF $0.87B − SBC $0.26B) capitalized at Kₑ (excluded from median) |
| Ben Graham Formula | Earnings | $7.10 | 11.94x | yes | EPS $0.22 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $2.29 | 37.02x | yes | BV $11.79 × (ROIC 1.6% / WACC 8.3%) (excluded from median) |
| P/Sales Sector | Relative | $43.20 | 1.96x | yes | Revenue $4.71B × sector P/S 5.0x |
| PEG Fair Value | Relative | $8.25 | 10.28x | yes | EPS $0.22 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $2.38 | 35.62x | yes | EPS $0.22 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $5.3b |
| Net debt / NOPAT (after-tax) | 5.68x |
| Net debt / operating income (pre-tax) | 5.00x |
| Interest coverage | 4.4x |
| Share count CAGR (buyback) | -1.0% |
| Burning cash | no |
Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 23.8%); the trailing year was depressed.
Bullet Takeaways
Microchip is a moat-rich embedded-control franchise coming out of a deep cyclical trough. Gross margin has recovered to 61.6% from a 52% bottom, and management declared the inventory correction complete with the largest booking month in nearly four years.
The price prices the recovery aggressively. At $99.71 (as of June 27, 2026) no valuation family reaches the price, and the embedded margin assumption is far above what the company earns today, so the buyer is paying for a full normalization.
The balance sheet is the constraint on patience. Net debt of about $5.26 billion against still-recovering earnings means coverage is tight near the trough, and management is prioritizing debt reduction over other uses of cash.
Bull Case
Microchip's competitive moat is the foundation of the thesis, and it is built on switching costs that compound over decades. The company develops "smart, connected and secure embedded control solutions," with a portfolio spanning "general purpose and specialized 8-bit, 16-bit, and 32-bit mixed-signal microcontroller" products plus analog and the surrounding software and tools (FY2025 10-K, accession 0000827054-25-000077). Once a microcontroller is designed into a product, replacing it means re-engineering the customer's hardware and firmware, so designs stick for the life of the end product, often many years. That stickiness is why Microchip earns high through-cycle margins and why a downturn is a pause, not a permanent loss. The franchise is concentrated in microcontrollers (50% of revenue) and analog (28%), the two highest-quality, longest-lived semiconductor categories.
The cyclical recovery is now visibly underway, and the operating leverage is powerful. Fiscal Q4 2026 revenue rose 35.1% year over year to $1.311 billion, topping guidance, and non-GAAP gross margin recovered to 61.6% from a 52% trough a year earlier as the nine-point recovery plan took hold. Management declared the inventory correction complete, with days of inventory falling to 185 from a peak of 266, and reported that April was the largest booking month in nearly four years. The recovery is broad-based across end markets, led by aerospace and defense and data center, and full-year non-GAAP net income rose 31.8% to $933.9 million.
The growth optionality and the capital-return record sweeten the recovery story. The Data Center Solutions business is scaling from about $303 million in revenue toward roughly $500 million, winning PCIe Gen6 switch designs and entering the retimer market aimed at AI infrastructure, a genuine new growth vector layered on the core franchise. Microchip has paid a dividend for 94 consecutive quarters, a discipline it maintained through the trough while prioritizing debt reduction, and the share count is shrinking modestly. A moat-rich embedded-control leader emerging from an inventory correction with gross margin already back above 61%, broad-based bookings recovery, and an AI-driven data-center kicker is the kind of franchise where the cyclical low is the opportunity.
Bear Case
The structural problem sits on the right side of the balance sheet: Microchip carries net debt of about $5.26 billion, and it took on that leverage before a brutal downcycle hollowed out its earnings. At the trough, interest coverage compressed to roughly 5 times and net debt ran above 5 times operating income, a precarious ratio for a cyclical semiconductor company. The 10-K notes that the senior-note indentures carry "customary affirmative and negative covenants, including covenants that limit or restrict the Company and its subsidiaries' ability to" take various actions (FY2025 10-K, accession 0000827054-25-000077), so the debt is not just a number, it constrains flexibility. Management is explicitly prioritizing debt reduction over buybacks, which tells you the balance sheet is the binding concern, not an afterthought.
The valuation prices a recovery that is far from fully earned. At $99.71, no valuation family reaches the price: the stock is rich on assets, earnings power, peer multiples, and even forward growth, with the blended X-ray figure near $20.39, a fraction of the price. The priced-in characterization is that the price is a bet beyond what any standard frame supports, with an implied operating margin around 77% and an implied duration of more than 19 years, figures that are only possible because today's trough margin of 10.4% is so depressed that the model must assume an extreme and prolonged normalization to reach the price. In plain terms, the market has already priced a complete, durable cyclical recovery, leaving no cushion if the upturn stalls.
The cyclicality cuts both ways, and the recovery's durability is unproven. The same inventory dynamics that crushed earnings can recur: the correction that just ended was severe, and semiconductor demand is notoriously prone to double-dips. Fab restructuring, including a Fab 2 closure with special charges, shows the company is still resizing its manufacturing footprint, and capacity underutilization charges decline only modestly as fabs ramp over a multi-year period. A company servicing $5.26 billion of net debt, with a price that assumes a near-perfect long-term margin recovery and a balance sheet that constrains its options, is exposed on two fronts at once: if the recovery slows, both the earnings and the ability to delever weaken together, and the price sits far above every method that values the business as it actually is today.
Valuation
Microchip trades above every conventional valuation frame, and the X-ray says so bluntly. Against the $99.71 price, no family reaches the price: it is rich on assets, earnings power, peers, and even forward growth, with the blended figure across six methods near $20.39, far below the quote. The priced-in characterization is that the price is a bet beyond what any standard frame supports. This is a deep-cyclical valuation: the price is anchored to a normalized future, not to the depressed present.
The priced-in math is extreme precisely because the current earnings are at a trough. The model holds a current operating margin of 10.4% but must assume an implied margin around 77% over an implied duration above 19 years to justify the price. Those numbers are not a forecast of 77% margins; they are the mathematical consequence of trying to support today's price off a trough earnings base. The more useful anchor is the mid-cycle operating margin of 23.8% the company has demonstrated historically: the price requires not just a return to that mid-cycle level but sustained growth well beyond it. The gross-margin recovery to 61.6% is real progress toward normalization, but the price assumes the normalization is complete and durable.
The balance sheet is the constraint the valuation underweights. Net debt of about $5.26 billion sits at roughly 4.7 times operating income on a mid-cycle basis and higher on trough earnings, with interest coverage near 5 times, and the indenture covenants limit flexibility (FY2025 10-K, accession 0000827054-25-000077). An investor here is underwriting that the embedded-control moat drives margins back toward and beyond mid-cycle, that the data-center growth vector materializes, and that the company delevers along the way, all of which the price already assumes is delivered.
Catalysts
Fiscal Q4 2026 results (ended March 31, 2026, reported May 2026) confirmed the cyclical turn. Revenue rose 35.1% year over year to $1.311 billion, above the high end of guidance, non-GAAP diluted EPS was $0.57, and non-GAAP gross margin recovered to 61.6% from a 52% trough. Management declared the inventory correction complete, with days of inventory down to 185 from a peak of 266, and called April the largest booking month in nearly four years. The pace of gross-margin recovery and the durability of bookings are the key near-term catalysts, and forward guidance pointed to continued sequential and year-over-year growth.
The data-center growth vector is the strategic catalyst. The Data Center Solutions business is scaling from about $303 million toward roughly $500 million in 2026, with six PCIe Gen6 switch design wins and a new entry into the retimer market aimed at AI infrastructure. Adoption of these products and their contribution to the mix is a potential upside catalyst that would diversify Microchip beyond its traditional cyclical end markets.
Deleveraging and capital allocation are the structural watch items. Management is prioritizing debt reduction, with operating cash flow resuming coverage of debt and the dividend, and the company maintained its 94-consecutive-quarter dividend record. Fab restructuring, including a Fab 2 closure with special charges, continues to resize the manufacturing footprint as underutilization charges decline gradually. Shares have run up sharply year to date on AI-driven demand and the recovery, so analyst views are mixed on valuation. The catalysts that would justify the price are sustained margin normalization toward mid-cycle and beyond, data-center growth, and visible debt reduction; the risk is a stalled recovery colliding with the leverage.
Peer Cohorts (Per Segment, With Filing Citations)
Semiconductor products (reported)
- NVDA (NVIDIA CORP)
- (no filing in the citation store)
- AMD (ADVANCED MICRO DEVICES INC)
- (no filing in the citation store)
- AVGO (Broadcom Inc.)
- (no filing in the citation store)
- QCOM (QUALCOMM INC/DE)
- (no filing in the citation store)
Technology licensing (reported)
- ALGM (ALLEGRO MICROSYSTEMS, INC.)
- (no filing in the citation store)
- SLAB (SILICON LABORATORIES INC.)
- (no filing in the citation store)
- NXPI (NXP Semiconductors N.V.)
- (no filing in the citation store)
- SWKS (SKYWORKS SOLUTIONS, INC.)
- (no filing in the citation store)
- QRVO (Qorvo, Inc.)
- (no filing in the citation store)
- CRUS (Cirrus Logic, Inc.)
- (no filing in the citation store)
- ON (ON Semiconductor Corporation)
- (no filing in the citation store)
- SMTC (SEMTECH CORP)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.